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Abstract
Background: Piperacillin (and piperacillin/tazobactam) is a commonly prescribed antibiotic and is
generally considered safe. We report a case of piperacillin induced bone marrow suppression.
Case presentation: A 19-year-old boy was being treated with piperacillin followed by piperacillin/
tazobactam for infected pancreatic pseudocyst. After 21 days of treatment, he developed
neutropenia and thrombocytopenia. These reversed promptly after stopping piperacillin/
tazobactam. The time course of events suggested that piperacillin was the cause of bone marrow
suppression in this patient.
Conclusion: Bone marrow suppression is a serious adverse effect of piperacillin, which should be
kept in mind while treating patients with this drug.
Background
Piperacillin is a commonly prescribed antibiotic and is
generally considered safe. We report a case of bone mar-
row suppression induced by piperacillin (and piperacil-
lin/tazabactam).
Case Report
A 19-year-old boy had an attack of idiopathic acute pan-
creatitis following which he developed a large pseudocyst
occupying the body and tail of the pancreas. Endoscopic
cystogastrostomy was done four months after the onset of
pancreatitis. Two weeks later, the patient presented with
high fever. Investigations revealed: hemoglobin 10.6 g/
dL; total leukocyte count (TLC) 9.3 × 109/L (neutrophils
58%, lymphocytes 38% and eosinophils 4%). Blockage of
the cystogastrostomy stent and infection in the cyst cavity
were suspected. The stent was removed and a nasocystic
drainage tube was placed for drainage of pus and irriga-
tion of cyst cavity. Pus was sent for culture and sensitivity,
and piperacillin and amikacin were started empirically.
Culture of pus obtained at the time of placement of naso-
cystic tube grew Pseudomonas aeruginosa (sensitive to pip-
eracillin, amikacin, piperacillin/tazobactam and
ciprofloxacin) and enterococcus species (sensitive to all
common antibiotics). His fever responded within three
days. However, 13 days later, he again developed high
fever inspite of antibiotics. Suspecting resistant organ-
isms, fresh cultures were sent and piperacillin was
replaced by piperacillin/tazobactam; amikacin was con-
tinued. Four days later, results of second pus culture
revealed growth of bacteroides species sensitive to metro-
nidazole, which was added. On fifth day following start of
piperacillin/tazobactam (i.e. 21 days after start of pipera-
cillin), the patient developed neutropenia and thrombo-
cytopenia (TLC 0.9 × 109/L [neutrophils 58%,
lymphocytes 40% and eosinophils 2%], absolute neu-
trophil count 0.52 × 109/L; platelets 72 × 109/L). His
hemoglobin remained normal. Suspecting bone marrow
suppression due to piperacillin or piperacillin/tazo-
bactam, the latter combination was discontinued imme-
diately. Metronidazole and amikacin were continued. His
absolute neutrophil count on the next day was 0.58 × 109/
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L. Four days after stopping the drug, it improved to 1.00 ×
109/l, and, on the sixth day, it became normal (8.4 × 109/
L). Platelet count followed a similar course (122 × 109/L
on day 6). The patient became afebrile within two days.
Discussion
Piperacillin is an aminobenzyl-penicillin derivative used
for treatment of infection with organisms like Pseu-
domonas aeruginosa, Enterobacteraceae, Escherichia coli, Pro-
teus mirabilis,  Klebsiella,  Enterobacter serratia,  Citrobacter,
Salmonella and Shigella spp [1]. In mild infections, a dose
of 4–12 g/day is used; however, serious infections require
a dose as high as 12–24 g/day [2,3]. Its known adverse
effects include hypersensitivity reactions, neurotoxicity,
hepatotoxicity, electrolyte and acid-base disturbances,
bleeding disorders, neutropenia and thrombocytopenia,
and rarely hemolytic anemia [1]. Piperacillin is suscepti-
ble to beta-lactamases; hence, tazobactam, a beta-lacta-
mase inhibitor, is often combined with piperacillin. This
combination (piperacillin 4 g, tazobactam 0.5 g) has an
extended spectrum of action against beta-lactamase pro-
ducing organisms. It is also one of the favorite drugs used
in "febrile neutropenia". Its adverse effects are similar to
those of piperacillin alone, except diarrhea, which was
reported more often with the combination [1].
Leucopenia is an uncommon but serious adverse effect of
piperacillin and other beta-lactam antibiotics. There have
been several previous reports of leucopenia and bone
marrow suppression following the use of piperacillin [4–
7], and piperacillin/tazobactam [8–10]. This bone mar-
row suppression is usually reversible, recovers with dis-
continuation of the drug and is possibly related to direct
toxicity to myeloid precursors [11]. Large cumulative
doses are needed and neutropenia rarely develops before
10 days of therapy [11,12]. Leucopenia is usually associ-
ated with mild thrombocytopenia. When anemia occurs,
it is most commonly immune-hemolytic type [13]. Also,
isolated thrombocytopenia, which is usually immune-
mediated, has been reported with piperacillin [14–17]
and piperacillin/tazobactam [18].
Our patient developed neutropenia 21 days after the start
of piperacillin treatment (and 5 days after change over to
piperacillin/tazobactam). In previous reports, neutrope-
nia has been reported 11 to 17 days after the therapy was
begun [8,9]. Our patient had received piperacillin in a
dose of 8 g/day and piperacillin/tazobactam in a dose of
13.5 g/day, with a cumulative piperacillin dose of 3547
mg/Kg body weight. In a previous report, bone marrow
suppression occurred in patients who had received a
cumulative piperacillin/tazobactam dose of 4919 ± 1975
mg/Kg, [8] i.e. 4372 ± 1755 mg/Kg body weight of piper-
acillin. The dose received by our patient falls within this
range.
Our patient was also receiving amikacin and metronida-
zole when bone marrow suppression was noticed. How-
ever, metronidazole had been administered beginning
only 12 hours prior to leucopenia and was thus unlikely
to be the cause. Amikacin, a widely used drug, has never
been implicated as a cause of bone marrow suppression.
Also, leucopenia and thrombocytopenia promptly
reversed with discontinuation of piperacillin /tazo-
bactam, while amikacin and metronidazole were contin-
ued.
Conclusion
Bone marrow suppression is a serious adverse effect of
piperacillin, which should be kept in mind while treating
patients with this drug. Since the frequency of this adverse
effect is not known, it may be difficult at present to recom-
mend routine monitoring for this complication. How-
ever, a vigil must be kept in patients who have received a
high cumulative dose.
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